Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR

Watchlist Manager
Arrowhead Pharmaceuticals Inc Logo
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Watchlist
Price: 21.44 USD 14.1% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
Arrowhead Pharmaceuticals Inc?
Write Note

Net Margin
Arrowhead Pharmaceuticals Inc

-2 741.4%
Current
-386%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 741.4%
=
Net Income
-538.6m
/
Revenue
19.6m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
2.7B USD
-2 741%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
316.8B USD
9%
US
Amgen Inc
NASDAQ:AMGN
145.1B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
113.2B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.7B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.3B EUR
-14%
Country US
Market Cap 2.7B USD
Net Margin
-2 741%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 316.8B USD
Net Margin
9%
Country US
Market Cap 145.1B USD
Net Margin
13%
Country US
Market Cap 119B USD
Net Margin
-5%
Country US
Market Cap 113.2B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.4B AUD
Net Margin
18%
Country US
Market Cap 82.7B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.3B EUR
Net Margin
-14%
No Stocks Found

Arrowhead Pharmaceuticals Inc
Glance View

Market Cap
2.7B USD
Industry
Biotechnology

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 329 full-time employees. The firm uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The firm is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The firm's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.

ARWR Intrinsic Value
27.98 USD
Undervaluation 23%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 741.4%
=
Net Income
-538.6m
/
Revenue
19.6m
What is the Net Margin of Arrowhead Pharmaceuticals Inc?

Based on Arrowhead Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -2 741.4%.